Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading ADFRA:6YH +0.74%82 PEG Ratio is 0.13 as of Jul. 18, 2026, which is 78% below its 10-year median of 0.60. GuruFocus rates FRA:6YH with a GF Score™ of 82/100 and a GF Value™ of €7.38. The stock has 2 warning signs investors should review. Among 48 Medical Distribution companies, Sopharma Trading AD ranks better than 97.92% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Sopharma Trading AD's PEG Ratio or its related term are showing as below:
FRA:6YH'
s PEG Ratio Range Over the Past 10 Years
Min: 0.13 Med: 0.6 Max: 7.46
Current: 0.14
During the past 13 years, Sopharma Trading AD's highest PEG Ratio was 7.46. The lowest was 0.13. And the median was 0.60.
FRA:6YH's PEG Ratio is ranked better than 97.92% of 48
companies
in the Medical Distribution industry
Industry Median: 1.945
vs FRA:6YH: 0.14
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Sopharma Trading AD (FRA:6YH) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Sopharma Trading AD PEG Ratio Related Terms
Sopharma Trading AD PEG Ratio Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma Trading AD's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD PEG Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Sopharma Trading AD (FRA:6YH) has a PEG Ratio of 0.13 as of Jul. 18, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Sopharma Trading AD and its competitors. This is 78% below median its historical median of 0.60. Over the past decade, Sopharma Trading AD's PEG Ratio has ranged from 0.13 to 7.46. According to the industry distribution chart, Sopharma Trading AD ranks #1 out of 48 companies in the Medical Distribution industry, placing it in the top 2.1%.
Is Sopharma Trading AD's PEG Ratio too high?
Sopharma Trading AD's current PEG Ratio of 0.13 is 78% below median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 7.46. The Medical Distribution industry median PEG Ratio is 1.95. Sopharma Trading AD's value of 0.13 is 93.3% below this industry median. Based on the distribution chart, Sopharma Trading AD ranks #1 out of 48 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's PEG Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #1 out of 48 companies for PEG Ratio. This places Sopharma Trading AD in the top 2% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.95. Sopharma Trading AD's value of 0.13 is 93.3% below this benchmark. Historically, Sopharma Trading AD's own PEG Ratio has ranged from 0.13 to 7.46 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 1.95, Sopharma Trading AD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Distribution company?
The median PEG Ratio among Medical Distribution companies is 1.95, based on 48 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current PEG Ratio of 0.13 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median PEG Ratio is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current PEG Ratio is 0.13, which is 78% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Sopharma Trading AD (FRA:6YH) has a current PEG Ratio of 0.13. The stock's GF Value™ is €7.38, compared to a current price of €2.74 — trading 62.9% below its estimated fair value. The current PEG Ratio is 0.13, which is 78% below median its 10-year median of 0.60 and 93.3% below the Medical Distribution industry median of 1.95. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Sopharma Trading AD (FRA:6YH), the current PEG Ratio is 0.13 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (FRA:6YH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.74 is trading 62.9% below its estimated GF Value™ of €7.38.
Key valuation signals for FRA:6YH:
PEG Ratio: 0.13 (78% below median its 10-year median of 0.60)
GF Value™: €7.38 vs. price of €2.74 (62.9% below fair value)
Industry Position: 93.3% below the Medical Distribution median (#1 of 48)
No single metric tells the full story. See the FRA:6YH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for FRA:6YH
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6YH has been successfully added to your 
